$MVIS

MVIS Plummets Over 20%: D. Boral Capital Downgrades The Stock Citing Revenue Uncertainty And Wider Q4 Loss

MicroVision (MVIS) shares fell over 20% after D. Boral Capital downgraded the stock to 'Hold' from 'Buy', citing Q4 revenue decline of 88% YoY to $0.2M and wider-than-expected loss per share of $0.12. The analyst cited revenue uncertainty and lack of near-term growth clarity. The company's cash position is $74.8M, with $43M in convertible notes issued in February 2026.

Original reporting
Published Aug 23, 2026, 7:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MVIS
Bearish
medium confidence
Mentioned
$MVIS
Relevance
6/10
AlphAI data visualization · based on stocktwits.com
Decision brief

The 30-second read

$MVISBearishMed
01

Why it matters

The downgrade and earnings miss drive a 19% intraday decline, reinforcing bearish sentiment for the stock.

02

Market read

MicroVision's weak earnings and downgrade create a short‑term trading opportunity for bearish positions.

03

What to watch

Recent $43 M convertible note issuance could provide runway, and cash reserves of $74.8 M may support near‑term operations.

Relevance 6/10Novelty 6/10Timing: intraday today

Background

MicroVision reported a severe Q4 revenue decline and a larger-than-expected loss, prompting an analyst downgrade.

Company-level read

Ticker impact

$MVISBearishMedium confidence
Context

D. Boral Capital downgraded MicroVision to Hold after Q4 results showing 88% revenue decline and a $0.12 loss per share, sending the stock down 19% intraday.

Expected impact

Further downside pressure expected if sentiment remains negative; potential bounce if guidance improves.

Evidence & confidence

MicroVision's revenue collapse and loss miss are material for a micro‑cap; the downgrade adds a fresh negative catalyst.

Market effects

Highlights weakness in the lidar/advanced sensing sector, potentially affecting peer valuations.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global impact beyond niche technology investors.

Counterpoint

If MVIS can secure a commercial contract soon, the stock may be oversold after the sharp drop.

Key entities

  • MicroVision Inc.

    Lidar and advanced sensing technology developer (ticker MVIS).

  • D. Boral Capital

    Equity research firm that downgraded MVIS to Hold.

Related articles

$FULCMed

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.

$MVISMedAI 8/10

MicroVision, Inc.: MicroVision Announces Pricing of $17.0 Million Public Offering

MicroVision (NASDAQ:MVIS) priced a public offering of 6.8 million units at $2.50 per unit, with each unit including one share and one immediately exercisable warrant to buy one share at $2.50, expiring five years after issuance. Gross proceeds are expected at about $17.0 million. Proceeds will fund general corporate purposes, including working capital and capex. Closing is expected around Aug. 17, 2026.

$MVISMedAI 8/10

MicroVision, Inc.: MicroVision Announces Launch of Proposed Public Offering

MicroVision (NASDAQ:MVIS) said it has commenced a proposed public offering of units, each unit consisting of one share of common stock (or a pre-funded warrant in lieu) and one warrant to buy one share. MicroVision will sell the shares and warrants, with final terms to be set at pricing. Net proceeds are for general corporate purposes, including working capital and capex.

$MVISMedAI 8/10

MicroVision, Inc.: MicroVision Reports Second Quarter 2026 Results and Highlights Commercial Momentum Across Multiple Markets

MicroVision (NASDAQ:MVIS) reported Q2 2026 revenue of $1.5 million versus $0.2 million a year earlier, with net loss of $36.9 million ($1.66 per share). Operating expenses rose to $24.9 million. The company highlighted Lidar 2.0 progress, MOVIA Air launches, IRIS integration deals, cash burn guidance of about $60 million, and a 1-for-15 reverse split.